Heron Therapeutics (NASDAQ:HRTX – Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $37.37 million for the quarter.
Heron Therapeutics Stock Up 1.8 %
HRTX opened at $1.72 on Friday. Heron Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.93. The company has a 50 day moving average of $1.65 and a two-hundred day moving average of $1.73. The company has a market cap of $261.61 million, a P/E ratio of -9.56 and a beta of 1.60.
Analyst Ratings Changes
Several research firms recently issued reports on HRTX. StockNews.com cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.00 price target on shares of Heron Therapeutics in a report on Wednesday, December 4th.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Stories
- Five stocks we like better than Heron Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Financial Services Stocks Investing
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.